RTS,S malaria vaccine pilots in three African countries
For the pilot studies, vaccine manufacturer GlaxoSmithKline is providing up to 10 million doses of the vaccine, the countries' ministries of health will lead the vaccine introduction through their national immunisation programmes, and WHO will provide scientific and technical leadership. The va...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2019-04, Vol.393 (10182), p.1685-1685 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1685 |
|---|---|
| container_issue | 10182 |
| container_start_page | 1685 |
| container_title | The Lancet (British edition) |
| container_volume | 393 |
| creator | Adepoju, Paul |
| description | For the pilot studies, vaccine manufacturer GlaxoSmithKline is providing up to 10 million doses of the vaccine, the countries' ministries of health will lead the vaccine introduction through their national immunisation programmes, and WHO will provide scientific and technical leadership. The vaccine will be given to young children starting at 5 and 6 months of age and up to 2 years, in areas where malaria is high burden and young children are at highest risk of dying from the disease, in four doses, Felicitas Zawaira, Director of Family and Reproductive Health in the WHO African Region, said at a press conference on April 23. The vaccine could also help to accelerate the realisation of the WHO Global Technical Strategy for Malaria 2016–2030, which aims to reduce the incidence of malaria by at least 90%, reduce malaria mortality rates by at least 90%, eliminate malaria in at least 35 countries, prevent a resurgence of malaria in all countries that are malaria-free, achieve near-term milestones for 2020 (including reductions in related incidence and mortalities of at least 40%) and the elimination of malaria in at least ten countries, and harness innovation and expand research. |
| doi_str_mv | 10.1016/S0140-6736(19)30937-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2217483984</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673619309377</els_id><sourcerecordid>2214955561</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-f6a75cd4d62cc1be0e79dc93e0a30051c3258e1475231bf456ad02f76eb12b713</originalsourceid><addsrcrecordid>eNqFkEtLAzEUhYMotlZ_gjLgpoKjyeTVrKQUX1AQbAV3IZO5g5F51GSm4L93pq1duHF1N9859_AhdE7wDcFE3C4wYTgWkooxUVcUKypjeYCGhEkWcybfD9FwjwzQSQifGGMmMD9GA0owZVTwIZKvy8X1IipNYbwz0dpY6yqIVq6omxC5Kmo-PEA0zb2zpops3VaNdxBO0VFuigBnuztCbw_3y9lTPH95fJ5N57GlijZxLozkNmOZSKwlKWCQKrOKAjYUY04sTfgEus08oSTNGRcmw0kuBaQkSSWhIzTe9q58_dVCaHTpgoWiMBXUbdBJQiSbUDVhHXr5B_2sW19163qKKc656Av5lrK-DsFDrlfelcZ_a4J1b1ZvzOpemyZKb8xq2eUudu1tWkK2T_2q7IC7LQCdjrUDr4N1UFnInAfb6Kx2_7z4ASkQhZ0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2214955561</pqid></control><display><type>article</type><title>RTS,S malaria vaccine pilots in three African countries</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Adepoju, Paul</creator><creatorcontrib>Adepoju, Paul</creatorcontrib><description>For the pilot studies, vaccine manufacturer GlaxoSmithKline is providing up to 10 million doses of the vaccine, the countries' ministries of health will lead the vaccine introduction through their national immunisation programmes, and WHO will provide scientific and technical leadership. The vaccine will be given to young children starting at 5 and 6 months of age and up to 2 years, in areas where malaria is high burden and young children are at highest risk of dying from the disease, in four doses, Felicitas Zawaira, Director of Family and Reproductive Health in the WHO African Region, said at a press conference on April 23. The vaccine could also help to accelerate the realisation of the WHO Global Technical Strategy for Malaria 2016–2030, which aims to reduce the incidence of malaria by at least 90%, reduce malaria mortality rates by at least 90%, eliminate malaria in at least 35 countries, prevent a resurgence of malaria in all countries that are malaria-free, achieve near-term milestones for 2020 (including reductions in related incidence and mortalities of at least 40%) and the elimination of malaria in at least ten countries, and harness innovation and expand research.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(19)30937-7</identifier><identifier>PMID: 31034365</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Child, Preschool ; Children ; Childrens health ; Cost-Benefit Analysis ; Developing countries ; Disease control ; Ghana ; Health care ; Humans ; Immunization ; Incidence ; Infant ; Kenya ; LDCs ; Leadership ; Malaria ; Malaria - economics ; Malaria - prevention & control ; Malaria Vaccines - economics ; Malaria Vaccines - supply & distribution ; Malawi ; Moeti, Matshidiso ; Mosquito Nets - economics ; Pilot Projects ; Pilots ; Reproductive health ; Vaccines ; Vaccines, Synthetic - economics ; Vaccines, Synthetic - supply & distribution ; Vector-borne diseases</subject><ispartof>The Lancet (British edition), 2019-04, Vol.393 (10182), p.1685-1685</ispartof><rights>2019 Elsevier Ltd</rights><rights>2019. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-f6a75cd4d62cc1be0e79dc93e0a30051c3258e1475231bf456ad02f76eb12b713</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2214955561?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,64361,64363,64365,65309,72215</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31034365$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adepoju, Paul</creatorcontrib><title>RTS,S malaria vaccine pilots in three African countries</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>For the pilot studies, vaccine manufacturer GlaxoSmithKline is providing up to 10 million doses of the vaccine, the countries' ministries of health will lead the vaccine introduction through their national immunisation programmes, and WHO will provide scientific and technical leadership. The vaccine will be given to young children starting at 5 and 6 months of age and up to 2 years, in areas where malaria is high burden and young children are at highest risk of dying from the disease, in four doses, Felicitas Zawaira, Director of Family and Reproductive Health in the WHO African Region, said at a press conference on April 23. The vaccine could also help to accelerate the realisation of the WHO Global Technical Strategy for Malaria 2016–2030, which aims to reduce the incidence of malaria by at least 90%, reduce malaria mortality rates by at least 90%, eliminate malaria in at least 35 countries, prevent a resurgence of malaria in all countries that are malaria-free, achieve near-term milestones for 2020 (including reductions in related incidence and mortalities of at least 40%) and the elimination of malaria in at least ten countries, and harness innovation and expand research.</description><subject>Child, Preschool</subject><subject>Children</subject><subject>Childrens health</subject><subject>Cost-Benefit Analysis</subject><subject>Developing countries</subject><subject>Disease control</subject><subject>Ghana</subject><subject>Health care</subject><subject>Humans</subject><subject>Immunization</subject><subject>Incidence</subject><subject>Infant</subject><subject>Kenya</subject><subject>LDCs</subject><subject>Leadership</subject><subject>Malaria</subject><subject>Malaria - economics</subject><subject>Malaria - prevention & control</subject><subject>Malaria Vaccines - economics</subject><subject>Malaria Vaccines - supply & distribution</subject><subject>Malawi</subject><subject>Moeti, Matshidiso</subject><subject>Mosquito Nets - economics</subject><subject>Pilot Projects</subject><subject>Pilots</subject><subject>Reproductive health</subject><subject>Vaccines</subject><subject>Vaccines, Synthetic - economics</subject><subject>Vaccines, Synthetic - supply & distribution</subject><subject>Vector-borne diseases</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkEtLAzEUhYMotlZ_gjLgpoKjyeTVrKQUX1AQbAV3IZO5g5F51GSm4L93pq1duHF1N9859_AhdE7wDcFE3C4wYTgWkooxUVcUKypjeYCGhEkWcybfD9FwjwzQSQifGGMmMD9GA0owZVTwIZKvy8X1IipNYbwz0dpY6yqIVq6omxC5Kmo-PEA0zb2zpops3VaNdxBO0VFuigBnuztCbw_3y9lTPH95fJ5N57GlijZxLozkNmOZSKwlKWCQKrOKAjYUY04sTfgEus08oSTNGRcmw0kuBaQkSSWhIzTe9q58_dVCaHTpgoWiMBXUbdBJQiSbUDVhHXr5B_2sW19163qKKc656Av5lrK-DsFDrlfelcZ_a4J1b1ZvzOpemyZKb8xq2eUudu1tWkK2T_2q7IC7LQCdjrUDr4N1UFnInAfb6Kx2_7z4ASkQhZ0</recordid><startdate>20190427</startdate><enddate>20190427</enddate><creator>Adepoju, Paul</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20190427</creationdate><title>RTS,S malaria vaccine pilots in three African countries</title><author>Adepoju, Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-f6a75cd4d62cc1be0e79dc93e0a30051c3258e1475231bf456ad02f76eb12b713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Child, Preschool</topic><topic>Children</topic><topic>Childrens health</topic><topic>Cost-Benefit Analysis</topic><topic>Developing countries</topic><topic>Disease control</topic><topic>Ghana</topic><topic>Health care</topic><topic>Humans</topic><topic>Immunization</topic><topic>Incidence</topic><topic>Infant</topic><topic>Kenya</topic><topic>LDCs</topic><topic>Leadership</topic><topic>Malaria</topic><topic>Malaria - economics</topic><topic>Malaria - prevention & control</topic><topic>Malaria Vaccines - economics</topic><topic>Malaria Vaccines - supply & distribution</topic><topic>Malawi</topic><topic>Moeti, Matshidiso</topic><topic>Mosquito Nets - economics</topic><topic>Pilot Projects</topic><topic>Pilots</topic><topic>Reproductive health</topic><topic>Vaccines</topic><topic>Vaccines, Synthetic - economics</topic><topic>Vaccines, Synthetic - supply & distribution</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adepoju, Paul</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adepoju, Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RTS,S malaria vaccine pilots in three African countries</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2019-04-27</date><risdate>2019</risdate><volume>393</volume><issue>10182</issue><spage>1685</spage><epage>1685</epage><pages>1685-1685</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>For the pilot studies, vaccine manufacturer GlaxoSmithKline is providing up to 10 million doses of the vaccine, the countries' ministries of health will lead the vaccine introduction through their national immunisation programmes, and WHO will provide scientific and technical leadership. The vaccine will be given to young children starting at 5 and 6 months of age and up to 2 years, in areas where malaria is high burden and young children are at highest risk of dying from the disease, in four doses, Felicitas Zawaira, Director of Family and Reproductive Health in the WHO African Region, said at a press conference on April 23. The vaccine could also help to accelerate the realisation of the WHO Global Technical Strategy for Malaria 2016–2030, which aims to reduce the incidence of malaria by at least 90%, reduce malaria mortality rates by at least 90%, eliminate malaria in at least 35 countries, prevent a resurgence of malaria in all countries that are malaria-free, achieve near-term milestones for 2020 (including reductions in related incidence and mortalities of at least 40%) and the elimination of malaria in at least ten countries, and harness innovation and expand research.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>31034365</pmid><doi>10.1016/S0140-6736(19)30937-7</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2019-04, Vol.393 (10182), p.1685-1685 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2217483984 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Child, Preschool Children Childrens health Cost-Benefit Analysis Developing countries Disease control Ghana Health care Humans Immunization Incidence Infant Kenya LDCs Leadership Malaria Malaria - economics Malaria - prevention & control Malaria Vaccines - economics Malaria Vaccines - supply & distribution Malawi Moeti, Matshidiso Mosquito Nets - economics Pilot Projects Pilots Reproductive health Vaccines Vaccines, Synthetic - economics Vaccines, Synthetic - supply & distribution Vector-borne diseases |
| title | RTS,S malaria vaccine pilots in three African countries |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T19%3A25%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RTS,S%20malaria%20vaccine%20pilots%20in%20three%20African%20countries&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Adepoju,%20Paul&rft.date=2019-04-27&rft.volume=393&rft.issue=10182&rft.spage=1685&rft.epage=1685&rft.pages=1685-1685&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(19)30937-7&rft_dat=%3Cproquest_cross%3E2214955561%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2214955561&rft_id=info:pmid/31034365&rft_els_id=S0140673619309377&rfr_iscdi=true |